Discovery of AZD3199, an inhaled ultralong acting β2 receptor agonist with rapid onset of action

ACS Medicinal Chemistry Letters

Volumn 5, Issue 4, 2014, Pages 416-421

  Stocks, Michael J ^a,b   Alcaraz, Lilian ^a   Bailey, Andrew ^a   Bonnert, Roger ^a   Cadogan, Elaine ^a   Christie, Jadeen ^a   Dixon, John ^a   Connolly, Stephen ^a   Cook, Anthony ^a   Fisher, Adrian ^a   Flaherty, Alice ^a   Humphries, Alexander ^a   Ingall, Anthony ^a   Jordan, Stephen ^a   Lawson, Mandy ^a   Mullen, Alex ^a   Nicholls, David ^a   Paine, Stuart ^a   Pairaudeau, Garry ^a   Young, Alan ^a  

^a ASTRAZENECA   (United Kingdom)

^b UNIVERSITY OF NOTTINGHAM   (United Kingdom)

Author keywords

adrenoreceptor agonist; asthma; AZD3199; COPD; inhaled; uLABA

Indexed keywords

AZD 3199; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BRONCHODILATING AGENT; CARBACHOL; FORMOTEROL; HISTAMINE; INDACATEROL; LONG ACTING DRUG; METHACHOLINE; SALBUTAMOL; SALMETEROL; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRONCHUS; CLINICAL EVALUATION; DRUG BINDING; DRUG DESIGN; DRUG MECHANISM; DRUG POTENCY; DRUG STRUCTURE; EXPERIMENTAL BRONCHOCONSTRICTION; GUINEA PIG; HUMAN; HUMAN TISSUE; NONHUMAN; PRIORITY JOURNAL; SYNTHESIS; TRACHEA;

EID: 84898048432     PISSN: None     EISSN: 19485875     Source Type: Journal    
DOI: 10.1021/ml4005232     Document Type: Article

References (28)

1. Fuso, L.; Mores, N.; Valente, S.; Malerba, M.; Montuschi, P. Long-acting beta-agonists and their association with inhaled corticosteroids in COPD Curr. Med. Chem. 2013, 20, 1477-1495
2. Walker, J. K. L.; Penn, R. B.; Hanania, N. A.; Dickey, B. F.; Bond, R. A. New perspectives regarding β(2)-adrenoceptor ligands in the treatment of asthma Br. J. Pharmacol. 2011, 163, 18-28
3. Cazzola, M.; Page, C. P.; Rogliani, P.; Matera, M. G. β2-agonist therapy in lung disease Am. J. Respir. Crit. Care Med. 2013, 187, 690-696
4. Matera, M. G.; Cazzola, M. Ultra-long-acting beta2-adrenoceptor agonists: an emerging therapeutic option for asthma and COPD? Drugs 2007, 67, 503-515
5. Bouyssou, T.; Hoenke, C.; Rudolf, K.; Lustenberger, P.; Pestel, S.; Sieger, P.; Lotz, R.; Heine, C.; Buettner, F. H.; Schnapp, A.; Konetzki, I. Discovery of olodaterol, a novel inhaled β2-adrenoceptor agonist with a 24 h bronchodilatory efficacy Bioorg. Med. Chem. Lett. 2010, 20, 1410-1414
6. Procopiou, P. A.; Barrett, V. J.; Bevan, N. J.; Biggadike, K.; Box, P. C.; Butchers, P. R.; Coe, D. M.; Conroy, R.; Emmons, A.; Ford, A. J.; Holmes, D. S.; Horsley, H.; Kerr, F.; Li-Kwai-Cheung, A.-M.; Looker, B. E.; Mann, I. S.; McLay, I. M.; Morrison, V. S.; Mutch, P. J.; Smith, C. E.; Tomlin, P. Synthesis and structure-activity relationships of long-acting β2 adrenergic receptor agonists incorporating metabolic inactivation: an antedrug approach J. Med. Chem. 2010, 53, 4522-4530
7. Davies, S. L.; Castaner, J. Indacaterol Drugs Future 2005, 30, 1219-1224
8. Roig, J.; Hernando, R.; Mora, R. Indacaterol, a novel once daily inhaled β2-adrenoreceptor agonist. Open Respir. Med. J. 2009, 3, 27-30
9. Baur, F.; Beattie, D.; Beer, D.; Bentley, D.; Bradley, M.; Bruce, I.; Charlton, S. J.; Cuenoud, B.; Ernst, R.; Fairhurst, R. A.; Faller, B.; Farr, D.; Keller, T.; Fozard, J. R.; Fullerton, J.; Garman, S.; Hatto, J.; Hayden, C.; He, H.; Howes, C.; Janus, D.; Jiang, Z.; Lewis, C.; Loeuillet-Ritzler, F.; Moser, H.; Reilly, J.; Steward, A.; Sykes, D.; Tedaldi, L.; Trifilieff, A.; Tweed, M.; Watson, S.; Wissler, E.; Wyss, D. The identification of indacaterol as an ultralong-acting inhaled β2-adrenoceptor agonist J. Med. Chem. 2010, 53, 3675-3684
10. Mortimer, K. J.; Harrison, T. W.; Tang, Y.; Wu, K.; Lewis, S.; Sahasranaman, S.; Hochhaus, G.; Tattersfield, A. E. Plasma concentrations of inhaled corticosteroids in relation to airflow obstruction in asthma Br. J. Clin. Pharmacol. 2006, 62, 412-419
11. Anderson, G. P.; Lindén, A.; Rabe, K. F. Why are long-acting beta-adrenoceptor agonists long-acting? Eur. Respir. J. 1994, 7, 569-578
12. Green, S. A; Spasoff, A. P.; Coleman, R. A.; Johnson, M.; Liggett, S. B. Sustained activation of a G protein-coupled receptor via "anchored" agonist binding. Molecular localization of the salmeterol exosite within the β2-adrenergic receptor J. Biol. Chem. 1996, 39, 24029-24035
13. Bao, Y.; Horst, L. Action mechanism of long- acting bronchodilators Acta Pharm. Sin. 1998, 20, 191-196
14. Deyrup, M. D.; Nowicki, S. T.; Richards, N. G. J.; Otero, D. H.; Harrsison, J. K.; Baker, S. P. Structure-affinity profile of 8-hydroxycarbostyril-based agonists that dissociate slowly from the beta2-adrenoceptor Arch. Pharmacol. 1999, 359, 168-177
15. Patton, J. S.; Byron, P. R. Inhaling medicines: delivering drugs to the body through the lungs Nat. Rev. Drug Discovery 2007, 6, 67-74
16. Cooper, A. E.; Ferguson, D.; Grime, K. Optimization of DMPK by the inhaled route: challenges and approaches Curr. Drug. Metab. 2012, 13, 457-473
17. Alikhani, V.; Beer, D.; Bentley, D.; Bruce, I.; Cuenoud, B. M.; Fairhurst, R. A.; Gedeck, P.; Haberthuer, S.; Hayden, C.; Janus, D.; Jordan, L.; Lewis, C.; Smithies, K.; Wissler, E. Long-chain formoterol analogues: an investigation into the effect of increasing amino-substituent chain length on the β2-adrenoceptor activity Bioorg. Med. Chem. Lett. 2004, 14, 4705-4710
18. White, M. V.; Sander, N. Asthma from the perspective of the patient J. Allergy Clin. Immunol. 1999, 104, s47-52
19. Kuna, P.; Ivanov, Y.; Trofimov, V. I.; Saito, T.; Beckman, O.; Bengtsson, T.; Jorup, C.; Maltais, F. Efficacy and safety of AZD3199 vs formoterol in COPD: a randomized, double-blind study Respir. Res. 2013, 14, 64
20. 2-agonists Bioorg. Med. Chem. Lett. 2011, 21, 4027-4031
21. Austin, R. P.; Barton, P.; Bonnert, R. V.; Brown, R. C.; Cage, P. A.; Cheshire, D. R.; Davis, A. M.; Dougall, I. G.; Ince, F.; Pairaudeau, G.; Young QSAR and the rational design of long-acting dual D2 -receptor/β2- adrenoceptor agonists J. Med. Chem. 2003, 46, 3210-3220
22. 2-adrenoceptor agonists Bioorg. Med. Chem. Lett. 2012, 22, 689-695
23. Procopiou, P. A.; Barrett, V. J.; Biggadike, K.; Butchers, P. R.; Craven, A.; Ford, A. J.; Guntrip, S. B.; Holmes, D. S.; Hughes, S. C.; Jones, A. E.; Looker, B. E.; Mutch, P. J.; Ruston, M.; Needham, D.; Smith, C. E. Discovery of a rapidly metabolized, long-acting β2 adrenergic receptor agonist with a short onset time incorporating a sulfone group suitable for once-daily dosing J. Med. Chem. 2014, 57, 159-170
24. Walland, A.; Palluk, R.; Burkard, S.; Hammer, R. Compensation of muscarinic bronchial effects of talsaclidine by concomitant sympathetic activation in guinea pigs Eur. J. Pharmacol. 1997, 330, 213-219
25. Connolly, S.; Alcaraz, L.; Bailey, A.; Cadogan, E.; Christie, J.; Cook, A. R.; Fisher, A. J.; Hill, S.; Humphries, A.; Ingall, A. H.; Kane, Z.; Paine, S.; Pairaudeau, G.; Stocks, M. J.; Young, A. Design-driven LO: the discovery of new ultra long acting dibasic β2-adrenoceptor agonists Bioorg. Med. Chem. Lett. 2011, 21, 4612-4616
26. Tayab, Z. R.; Hochhaus, G. Pharmacokinetic/pharmacodynamic evaluation of inhalation drugs: application to targeted pulmonary delivery systems Expert Opin. Drug. Delivery 2005, 2, 519-532
27. Bailey, A.; Bonnert, R.; Flaherty, A.; Pairaudeau, G.; Stocks, M. WO 2007027133, 2007.
28. Giles, M. E.; Thomson, C.; Eyley, S. C.; Cole, A. J.; Goodwin, C. J.; Hurved, P. A.; Morlin, A. J. G.; Tornos, J.; Atkinson, S.; Just, C.; Dean, J. C.; Singleton, J. T.; Longton, A. J.; Woodland, I.; Teasdale, A.; Gregertsen, B.; Else, H.; Athwal, M. S.; Tatterton, S.; Knott, J. M.; Thompson, N.; Smith, S. Development of a manufacturing process for sibenadet hydrochloride, the active ingredient of Viozan J. Org. Process Res. Dev. 2004, 8, 628-642